This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Safety

Somavert has an established safety profile1-2

​​​​​​​Most common adverse events:

- Headaches (25%)1
- Arthralgia (16%)1
- Diarrhoea (13%)​​​​​​​1


Adverse events of interest:

Abnormal liver results (≥1/100 to <1/10)1 
- 3.2% of 2221 patients from ACROSTUDY had ALT/AST > 3 x ULN2
- Most elevations are transient with no reports of liver failure2

Injection site reactions (≥1/100 to <1/10)1
- 2% of 2221 patients from ACROSTUDY had treatment-related Injection site reactions2
- Most injection site reactions characterised as localised erythemas and soreness, spontaneously resolved with local symptomatic treatment, while pegvisomant therapy continued. Occurrence of injection site hypertrophy has been observed, including lipohypertrophy.1
​​​​​​​

Somavert safety profile

Over 2000 patients have participated in ACROSTUDY, the global safety surveillance study for Somavert to date, providing a wealth of information about possible adverse events1,2


For full details on side effects and selected adverse reactions please refer to the Somavert Summary of Product Characteristics1

Card CTA

** This is an optional area where footnotes can live.

Monitoring of liver tests (LT)

Liver function should be assessed at baseline and monitored every 4-6 weeks for the first 6 months of treatment, or at any time in patients exhibiting symptoms suggestive of hepatitis. More frequent if elevations are detected at baseline. For full details regarding the assessment and monitoring of liver function please refer to the Summary of Product Characteristics.​​​​​​​1

Somavert efficacy

Discover IGF-I normalisation rates with Somavert

Learn more

Track IGF-I, symptoms and co-morbidities with ACRODAT

Learn more

Contact us

To find out more about ACRODAT, supporting your patients or to order starter kits

Contact us

** This is an optional area where footnotes can live.

Starter kits

Help your patients feel confident with Somavert and self-administration 

Learn more

** This is an optional area where footnotes can live.
References​​​​​
  1. Somavert Summary of Product Characteristics. Great Britain available here. Northern Ireland available here 
  2. Fleseriu M, et al. More then a decate of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol, 2021;185(4):525-38.
PP-SOM-GBR-1122. January 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?